Ten year follow-up of patients with chronic hepatitis C treated with interferon

Hepato-Gastroenterology

Volumn 46, Issue 28, 1999, Pages 2447-2450

  Ajello, Antonino ^a   Freni, Maria Antonietta ^a   Spadaro, Aldo ^a   Alessi, Nunziata ^a   Impellizzeri, Francesco ^a   Consolo, Pierluigi ^a   Resta, Maria Letizia ^a   Ferraú, Oscar ^a  

^a NONE

Author keywords

Chronic hepatitis C; Interferon; Long term follow up

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ULTRASOUND; VIREMIA;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 0032827773     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N Engl J Med 1986; 315:1575-1578.
2. Tinè F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13:192-199.
3. Malaguarnera P, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato BA: Interferon alpha treatment in patients with chronic hepatitis C. A meta-analytic evaluation. Clin Drug Investig 1995; 9:141-149.
4. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Saius M, Costa JM, Vidaud M, Chaput JC, and the Multicenter Study Group: A comparison of three interferon-alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332:1457-1462.
5. Reichard O, Foberg U, Frydèn A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with Interferon-alpha-2b for 60 weeks. Hepatology 1994; 19:280-285.
6. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, Kamada T: Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19:871-875.
7. Lau JY, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL: Discrepancy between biochemical and virological responses to Interferon-alpha in chronic hepatitis C. Lancet 1993; 342:1208-1209.
8. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, Solinas A, Deplano A, Tocco A, Cossu P, Chien D, Kuo G, Polito A, Weiner AJ, Houghton M, Verme G, Bonino F, Rizzetto M: Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon alpha 2b. Hepatology 1993; 18:1300-1305.
9. Reichard O, Glaumann H, Frydèn A, Norkrans G, Schvarcz R, Sonnerborg A, Yun ZB, Weiland O: Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to Interferon-alpha-2b treatment. Hepatolagy 1995; 21:918-922.
10. Booth JC, Brown JL, Thomas HC: The management of chronic hepatitis C infection. Gut 1995; 37:449-454.
11. Shindo M, Di Bisceglie AM, Hoofnagle JH: Long term follow up of patients with chronic hepatitis C treated with alpha-Interferon, Hepatology 1992; 15:1013-1016.
12. Marcellin P, Boyer N, Degott P, Martinot-Peignoux M, Duchatelle V, Giostra E, Areias J, Erlinger S, Benhamou JP: Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha Interferon. Liver 1994; 14:302-307.
13. De Alava E, Camps J, Pardo-Mindàn J, Garcia-Granero M, Munoz M, Sola J, Civeira MP, Contreras F, Vàzquez JJ, Castilla A, Prieto J: Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alpha Interferon. Liver 1993; 13:73-79.
14. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J: Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17:390-396.
15. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21:291-297.
16. Hagiwara H, Hayashi N, Mita E, Takahara T, Kasahara A, Fusamoto H, Kamada T: Quantitative analysis of hepatitis C virus RNA in serum during interferon-alpha therapy. Gastroenterology 1993; 104:877-883.
17. Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC: Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon alpha. Gut 1995; 36:427-432.
18. Realdi G, Alberti A, Rugge A, Rigoli AM, Tremolada F, Schivazappa L, Ruol A: Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23:270-275.
19. Koretz RL, Stone O, Gitnick GL: The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterol 1980; 79:893-898.
20. Takahashi M, Yamada G, Miyamoto R, Toshihiko D, Endo H, Tsuji T: Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240-243.
21. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G: Long-term follow-up of non-A, non-B (type C) post-transfusion Hepatitis. J Hepatol 1992; 16:273-281.
22. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CC, and the National Heart, Lung, and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327:1906-1911.
23. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
24. Kiyosawa K, Akahane Y, Nagata A, Koike Y, Furuta S: Significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox sanguinis 1982; 43:45-52.
25. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, and the TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-706.
26. Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzky S, Gerotto M, Levrero M, Artini M, Baldi M, Bellardini G, Barbara L: Distribution of three major hepatitis C virus genotypes in Italy. A multicenter study of 495 patients with chronic hepatitis C. Journal of Viral Hepatitis 1995; 2:33-38.
27. Pozzato G, Moretti M, Franzin F, Croce LS, Tiribelli C, Masayu T, Kaneko S, Unoura M, Kobayashi K: Severity of liver disease with different HCV clones. Lancet 1991; 338:509.
28. Kiyosawa K, Akahane Y, Negata A, Fumita S: Hepatocellular carcinoma after non-A, non-B post-transfusion hepatitis. Am J Gastroenter 1984; 79:777-781.